Skip to content

US · NGEN · BIOTECHNOLOGY

NervGen Pharma Corp. Common stock (NGEN) intrinsic value and stock valuation

$1.85as of 2026-11-21 · Mkt cap 138.08M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NervGen Pharma Corp. Common stock DCF and intrinsic value

InvestorsCraft values NGEN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NGEN’s statements →

NervGen Pharma Corp. Common stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology West Vancouver, BC V6Z 2R4 nervgen.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-44.12M
20172025
Free cash flow
-$-19.5M
20182025
Total equity
$3.48M-10.1% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-25.08M-$-24.92M-$-17.78M-$-22.82M-$-12.91M
Net income-$-44.12M-$-23.99M-$-22.38M-$-20.54M-$-12.82M
EPSd-$-609.98K-$-356.36K-$-377.47K-$-390.12K-$-326.29K
Operating cash flow-$-19.5M-$-16.83M-$-11.3M-$-17.63M-$-8.33M
Capital expenditure$0.00$0.00-$-10K-$-20K-$0.00
Free cash flow-$-19.5M-$-16.83M-$-11.3M-$-17.65M-$-8.33M
Total assets$23.2M$19.5M$13.2M$23.7M$18M
Total debt$10K$110K$200K$280K$0.00
Net debt-$-22.06M-$-17.15M-$-11.46M-$-21.97M-$-17.06M
Total equity$3.48M$2.57M-$-2.01M$13.3M$17M
Cash and short-term investments$22.1M$17.4M$11.7M$22.3M$17.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$80K$150K$110K$40K
Gross profit$0.00-$-80K-$-150K-$-110K-$-40K
Research and development expenses$13.9M$15.7M$8M$16.4M$6.88M
Selling, general and administrative expenses$11.2M$9.17M$9.63M$6.28M$5.98M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$25.1M$24.8M$17.6M$22.7M$12.9M
Cost and expenses$25.1M$24.9M$17.8M$22.8M$12.9M
Interest income$330K$810K$550K$200K$30K
Interest expense$0.00$0.00$0.00$510K$0.00
Depreciation and amortization$60K$80K$150K$110K$40K
Ebitda-$-5.65M-$-23.91M-$-22.24M-$-19.92M-$-12.78M
Operating income-$-25.08M-$-24.92M-$-17.78M-$-22.82M-$-12.91M
Total other income/expenses, net-$-19.04M$930K-$-4.61M$2.28M$90K
Income before tax-$-44.12M-$-23.99M-$-22.38M-$-20.54M-$-12.82M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-44.12M-$-23.99M-$-22.38M-$-20.54M-$-12.82M
Weighted average shares outstanding$72.3M$67.3M$59.3M$52.7M$39.3M
Weighted average diluted shares outstanding$72.3M$67.3M$59.3M$52.7M$39.3M
Balance sheet
20252024202320222021
Cash and short-term investments$22.1M$17.4M$11.7M$22.3M$17.1M
Net receivables$80K$420K$250K$30K$60K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$22.8M$19M$12.5M$22.9M$17.6M
Property, plant and equipment, net$0.00$0.00$200K$290K$0.00
Goodwill and intangible assets$410K$460K$520K$430K$480K
Long-term investments$0.00$10K$0.00$0.00$0.00
Total non-current assets$410K$470K$720K$720K$480K
Total assets$23.2M$19.5M$13.2M$23.7M$18M
Accounts payable$4.66M$0.00$0.00$0.00$0.00
Short-term debt$10K$100K$90K$90K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$19.7M$16.9M$15.1M$10.1M$1.09M
Long-term debt$0.00$10K$110K$200K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$10K$110K$200K$0.00
Capital lease obligations$10K$10K$110K$200K$0.00
Total liabilities$19.7M$16.9M$15.3M$10.3M$1.09M
Common stock$103M$81.1M$58.9M$56.9M$42.7M
Retained earnings-$-146.76M-$-102.09M-$-78.16M-$-55.28M-$-35.32M
Accumulated other comprehensive income (loss)$0.00$23.6M$17.2M$11.7M$9.54M
Total equity$3.48M$2.57M-$-2.01M$13.3M$17M
Total investments$0.00$110K$0.00$0.00$0.00
Total debt$10K$110K$200K$280K$0.00
Net debt-$-22.06M-$-17.15M-$-11.46M-$-21.97M-$-17.06M
Cash flow statement
20252024202320222021
Net income-$-44.12M-$-23.99M-$-22.38M-$-20.54M-$-12.82M
Depreciation and amortization$60K$80K$150K$110K$40K
Stock-based compensation$5.39M$0.00$0.00$0.00$0.00
Change in working capital$660K$840K-$-240K$2.1M$430K
Accounts receivable$330K-$-160K-$-220K$40K-$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-270K$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-19.5M-$-16.83M-$-11.3M-$-17.63M-$-8.33M
Investments in property, plant and equipment$0.00$0.00-$-140K-$-20K-$-50K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$100K$60K-$-140K-$-20K-$-50K
Common stock issued$24.8M$22.8M$870K$22.5M$19.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$23.8M$22.7M$770K$22.4M$19.8M
Net change in cash$4.8M$4.6M-$-10.29M$4.27M$11.5M
Cash at end of period$22.1M$17.3M$11.7M$22.3M$17.1M
Operating cash flow-$-19.5M-$-16.83M-$-11.3M-$-17.63M-$-8.33M
Capital expenditure$0.00$0.00-$-10K-$-20K-$0.00
Free cash flow-$-19.5M-$-16.83M-$-11.3M-$-17.65M-$-8.33M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NervGen Pharma Corp. Common stock

        NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

        CEO
        Adam H. Rogers
        Employees
        7
        Beta
        0.69

        Explore

        Frequently asked questions

        What is the intrinsic value of NervGen Pharma Corp. Common stock (NGEN)?

        InvestorsCraft does not currently publish an intrinsic value for NGEN. How the IC value is calculated.

        Is NGEN undervalued?

        InvestorsCraft does not publish an undervaluation signal for NGEN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.